KHIDI Regenerative Medicine R&D (seed)
Funds Korean and partner teams advancing cell and gene therapies and tissue engineering in frontier healthcare innovation.
KHIDI identifies regenerative medicine as one of three priority next-generation healthcare technology areas within its Health Industry R&D support mandate, alongside innovative new drugs and medical devices. The regenerative medicine programme funds R&D in cell therapy, gene therapy, and tissue engineering — the three primary modalities of the field — with the goal of advancing Korea's position in what KHIDI characterises as a high-potential, high-investment-requirement sector. This framing places regenerative medicine alongside big-data and AI health applications as a strategic priority receiving focused public investment.
Eligible applicants include Korean-registered for-profit companies, universities, hospitals, and research institutes, consistent with KHIDI's broader healthcare R&D eligibility criteria. Applications are submitted through the KHIDI EPS portal in Korean, and non-Korean entities typically require a domestic Korean partner to serve as the primary applicant. Whether regenerative medicine R&D is funded as a standalone call or as a dedicated track within the umbrella Health Industry R&D Promotion programme requires verification against current cycle announcements; the structured record flags this as an open question pending Korean-portal confirmation. Specific award sizes are not published in the available sources.
The regenerative medicine landscape funded by KHIDI spans early-stage cell and gene therapy R&D through translational programmes with commercialisation pathways. Competitive applications will demonstrate scientific credibility in one of the three core modalities — cell, gene, or tissue — clear alignment with KHIDI's priority areas, and a consortium that bridges laboratory expertise with clinical validation capability. International applicants and companies with regenerative medicine platforms can engage through partnerships with Korean academic medical centres or biotechnology companies registered in Korea.
Funds Korean R&D in cell therapy, gene therapy, and tissue engineering as a priority next-generation healthcare technology area within KHIDI's annual health industry support mandate.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline